Medicine
Xolremdi 100 mg capsule
Xolremdi 100 mg capsule is a prescription medicine containing Mavorixafor for oral use, marketed by X4 Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store XOLREMDI refrigerated at 2°C to 8°C (36°F to 46°F). Store in and…
Key facts
- Active ingredient (INN)
- Mavorixafor
- Brand
- Xolremdi
- Strength
- 100 mg
- Dosage form
- Capsule
- Route
- Oral
- Packs
- 120 capsules, 60 capsules, 90 capsules
- Marketing authorisation holder
- X4 Pharmaceuticals
- Manufacturer
- X4 Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store XOLREMDI refrigerated at 2°C to 8°C (36°F to 46°F). Store in and dispense from original container to protect from moisture.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L03AX24 Mavorixafor
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 May 2024
- Identifiers
- RxCUI 2684026, 2684032DailyMed set ID 7f3a5ee3-ca73-4876-85a0-ed1e108a2237NDC 83296-100Application NDA218709
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 120 capsule, gelatin coated in 1 bottle | 83296-100-12 | X4 Pharmaceuticals | 21 May 2024 |
| 60 capsule, gelatin coated in 1 bottle | 83296-100-60 | X4 Pharmaceuticals | 21 May 2024 |
| 90 capsule, gelatin coated in 1 bottle | 83296-100-90 | X4 Pharmaceuticals | 1 November 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Mavorixafor is a CXC chemokine receptor 4 antagonist indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. MedsAcross supplies Mavorixafor for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MavorixaforFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- XOLREMDI prescribing information (X4 Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Xolremdi: European public assessment report (EPAR) · European Medicines Agency
Need Xolremdi 100 mg capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.